DGA S.A. Logo

DGA S.A.

Consulting, training, and EU-funded project services for public and private organizations.

DGA | WAR

Overview

Corporate Details

ISIN(s):
PLDGA0000019 (+1 more)
LEI:
259400DTDT4GWZLEL890
Country:
Poland
Address:
Poznań Towarowa 37, 61-896 Poznań
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DGA S.A. is a consulting and advisory group with over 35 years of experience in providing innovative solutions and professional guidance. The company's core activities include business and management consulting, corporate restructuring advisory, and the implementation of comprehensive training programs for both individuals and organizations. DGA specializes in acquiring and executing projects co-financed by external sources, including European Union funds. The firm actively fosters innovation through incubation and acceleration programs for startups and social initiatives. Its diverse service portfolio also covers labor market activation, educational development programs, and specialized coaching. DGA serves a broad clientele, ranging from micro to large enterprises, public institutions, and non-governmental organizations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 17:17
Interim Report
Oświadczenie Zarządu
Polish 1.0 MB
2025-09-30 17:17
Audit Report / Information
Raport z przeglądu sprawozdania finansowego DGA S.A.
Polish 411.5 KB
2025-09-30 17:17
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności DGA S.A. za I półrocze 2025 r
Polish 1.5 MB
2025-09-30 17:17
Annual / Quarterly Financial Statement
Sprawozdanie finansowe DGA S.A. za I półrocze 2025 r.
Polish 1.8 MB
2025-07-31 14:15
Regulatory News Service
Zawiadomienie o zejściu poniżej progu 5% ogólnej liczby głosów w Spółce - Conte…
Polish 1.8 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie akcjonariusza
Polish 78.4 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie o przekroczeniu progu 5% ogólnej liczby głosów w Spółce - Content…
Polish 1.2 KB
2025-07-29 13:56
Regulatory News Service
Otrzymanie podpisanego egzemplarza umowy znaczącej - Content (PL)
Polish 475 bytes
2025-07-17 15:22
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 1.3 KB
2025-05-29 17:26
Management Discussion and Analysis
Informacje uzupełniające i komentarz Zarządu
Polish 1.5 MB
2025-05-29 17:26
Quarterly Report
Jednostkowe sprawozdanie finansowe DGA S.A. za I kw. 2025 r.
Polish 1.7 MB
2025-05-22 16:05
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish 1.0 KB
2025-05-22 15:56
Post-Annual General Meeting Information
Treść podjętych uchwał
Polish 204.0 KB
2025-05-22 15:56
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie w dniu 22 maja 2025 r…
Polish 751 bytes
2025-04-24 15:10
Environmental & Social Information
Podpisanie umowy na realizację projektu. pt. "Zielona gospodarka - szkolenia i …
Polish 1.0 KB

Automate Your Workflow. Get a real-time feed of all DGA S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DGA S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.